Adelaide Research & Scholarship: Search

Search

Results 1-10 of 16 (Search time: 0.003 seconds).

previous
1
2
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2018	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells	Ross, D.; Pagani, I.; Shanmuganathan, N.; Kok, C.; Seymour, J.; Mills, A.; Filshie, R.; Arthur, C.; Dang, P.; Saunders, V.; Braley, J.; Yong, A.; Yeung, D.; White, D.; Grigg, A.; Schwarer, A.; Branford, S.; Hughes, T.
	2012	Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells	Wang, J.; Hughes, T.; Kok, C.; Saunders, V.; Frede, A.; Groot Obbink, K.; Osborn, M.; Somogyi, A.; D'Andrea, R.; White, D.
	2013	Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells	White, D.; Eadie, L.; Saunders, V.; Hiwase, D.; Hughes, T.
	2010	Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy	Hiwase, D.; White, D.; Zrim, S.; Saunders, V.; Vaz de Melo, J.; Hughes, T.
	2010	Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity	Engler, J.; Frede, A.; Saunders, V.; Zannettino, A.; Hughes, T.; White, D.
	2010	Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors	Hiwase, D.; White, D.; Powell, J.; Saunders, V.; Zrim, S.; Frede, A.; Guthridge, M.; Lopez, A.; D'Andrea, R.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.
	2010	The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells	Engler, J.; Frede, A.; Saunders, V.; Zannettino, A.; White, D.; Hughes, T.
	2006	OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib	White, D.; Saunders, V.; Dang, P.; Engler, J.; Zannettino, A.; Cambareri, A.; Quinn, S.; Manley, P.; Hughes, T.
	2007	Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity	White, D.; Saunders, V.; Dang, P.; Engler, J.; Venables, A.; Zrim, S.; Zannettino, A.; Lynch, K.; Manley, P.; Hughes, T.
	2007	Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugs	White, D.; Saunders, V.; Quinn, S.; Manley, P.; Hughes, T.